Media Contact:
Helen Chernikoff
hchernikoff@hadassah.org
NEW YORK, NY – Male mice with Type 1 diabetes showed increased resistance to femur fracture after treatment with two drugs that clear the body of old cells, according to research presented by Rivka Dresner-Pollak, MD, director of the Department of Endocrinology and Metabolism at the Hadassah Medical Organization in Jerusalem. The results show that the drug combination has the potential to improve bone health in humans with Type 1 diabetes, who are at higher risk of hip and other bone fractures than people who do not have Type 1 diabetes.
Dr. Dresner-Pollak spoke at ENDO 2024, the annual conference of the Endocrine Society, in Boston, MA, on June 2.
She presented a study in which three-month-old male mice with Type 1 diabetes were given four monthly treatments of Dasatinib and Quercetin, members of the “senolytics” class of drugs, which help clear the body of cells that no longer multiply but also do not die. Instead, they begin to secrete a variety of chemicals, including some that can contribute to bone fragility.
The diabetic mice showed higher levels of these destructive chemicals at three months than a non-diabetic control group. However, after being given Dasatinib and Quercetin for the next four months, the mice demonstrated signs of healthier, stronger bones.
ABOUT THE HADASSAH MEDICAL ORGANIZATION:
For more than a century, the Hadassah Medical Organization, the Jerusalem-based hospital system founded and owned by Hadassah, The Women’s Zionist Organization of America, has set the standard for excellence in medical treatment and research in Israel. The experience and ingenuity of Hadassah’s doctors and scientists have yielded ideas with vast potential in all areas of medicine, including therapeutics, diagnostic medical devices and digital health.